The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Phase Ib MagnetisMM-30 trial of elranatamab with iberdomide in R/R multiple myeloma
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses early results from the Phase Ib MagnetisMM-30 trial (NCT06215118) evaluating elranatamab with iberdomide in relapsed/refractory (R/R) multiple myeloma. He highlights deep responses with manageable safety. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
